In this Issue:
Effects of probiotic type, dose and duration on IBS
Statins reduce CRC risk in IBD
T1 CRC management after endoscopic treatment according to lymph node metastasis
Cross-immunogenicities of infliximab originator and biosimilar
Dysbiosis and N. flavescens strain in duodenum in coeliac disease
Symptoms of depression and CD exacerbation
DAA regimen in HCV infection with concomitant acid-reducing agents
Mixed fibre vs. psyllium for chronic constipation
Environmental risk factors for IBD
Cancer recurrence after immunosuppressants for immune-mediated diseases
Please login below to download this issue (PDF)